Share this content on Facebook!
13 Nov 2014

4. Financial guidance for 2014 confirmed; important milestones expected for the remainder of the year All of the financial targets published on 25 March 2014 in Evotec's Annual Report 2013 (page 69) remain unchanged. In 2014, total Group revenues excluding milestones, upfronts and licences are expected to see high single-digit percentage growth. Evotec expects research and development (R&D) expenses in 2014 to increase above the levels of 2013. This is primarily due to additional investments in the strategic Cure X and Target X franchise. In total, R&D expenditure is expected to be in the range of EURO 10 m to EURO 14 m in 2014.
For the original version including any supplementary images or video, visit

To read more about malarone malaria tablets please visit


There isn't any comment in this page yet!

Do you want to be the first commenter?

New Comment

Full Name:
E-Mail Address:
Your website (if exists):
Your Comment:
Security code: